NCT07614061

Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-05Est. Completion: 2028-12

Enrollment target: 18 participants

Locations

Contact

EGFR OverexpressionLocally Advanced Solid TumorMetastatic Solid Tumor

This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Ad…

Seoul, South KoreaEst. completion Jun 2027

Biliary Tract Cancer (BTC)

According to current clinical guidelines, first-line treatment for advanced biliary tract cancer (BTC) is the gemcitabin…

Shanghai, ChinaEst. completion Jun 15, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.